Skip to main content
. Author manuscript; available in PMC: 2013 Feb 1.
Published in final edited form as: Am J Cardiol. 2011 Nov 24;109(3):370–377. doi: 10.1016/j.amjcard.2011.09.023

Figure 1.

Figure 1

Absolute standardized differences of 45 baseline characteristics between patients receiving and not receiving warfarin, before and after propensity score matching (*Symptoms experienced during atrial fibrillation in the last six months; **Hospitalization for qualifying episodes of atrial fibrillation; ACE = angiotensin-converting enzyme; HTN = hypertension; NYHA = New York Heart Association; PND = paroxysmal nocturnal dyspnea)